Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Latest News

Market capUnder $100B
All Over $50MOver $300MOver $2BOver $10B
All Under $1BUnder $10BUnder $100BUnder $500B
SectorsAll
Filter by sector
Sunday, October 18, 2026· 8135 stock ideas· 217 writers·
18,714 views· 8,672 clicks

From X

@kevin__mak

Kevin Mak on X

$NKTR Lots of funky action in this name the past few days, some specific to the ongoing court case and some from bio as a whole. Let's unpack it. The jury note, paraphrased as "Is there a difference between breach + $1 and no breach + $0?", spooked the market and sent the stock down sharply. Two sides to this. First, the note is informative, but only a little. It tells us at least one juror sees the $0/$1 outcome as part of their possible resolution space. Where I think the market (or at least fintwit) got it wrong is treating the note as the voice of the entire jury. It could reflect the whole panel, or it could be a single juror's question. It doesn't even tell us direction: it could come from a juror looking for a way to find breach despite doubting the damages case. The price action implied the whole jury is now choosing between $0 and $1, which I think is a big overread. Second, this is NKTR: a retail/fintwit-heavy, relatively illiquid SMID-cap biotech that moves 5% on a random Tuesday with no news. A 10% move on this headline looks extreme, but near-term price action here mostly reflects value-agnostic traders playing local news and liquidity flow, not a considered repricing of long-term value. The bigger picture: the case is largely a distraction from the real value, which is Rezpeg. I'm not a biotech expert, but the sell side and most biotech specialists I respect see it as a likely viable commercial product that's underpriced here. If anything, the case matters mainly as an overhang. An uncertain $0-to-$1B+ claim is hard for any acquirer or partner to price, so resolution in almost any direction clears the path for corporate action. The distraction is creating the opportunity. Disclosure: Creek Drive and its affiliated funds holds a long position in NKTR. Views expressed are current opinions for information only, subject to change and are not investment advice or a recommendation to buy or sell any security. Investing involves the risk of loss and past performance is not indicative of future performance. See the disclosures link in my bio for more important information.
@calvinblissett 2 clicks

Calvin Blissett on X

Hey Drew I know you cover mainly big names which makes sense in terms of reach. I watch your videos even when I know I’m not going to buy the stock because the quality is that good. I think in terms of bigger names with potential value $SLM is very interesting and would be a good set up for you. $KNSL is another that also has a pretty good retail following. $FISV is the biggest size potential value I’ve found. Also a $FICO update with thoughts would be orgasmic
@calvinblissett

Calvin Blissett on X

To me that is not true and one of the common misconceptions on $BMBL, like someone insightfully mentioned word of mouth is a powerful thing. Especially in today’s day and age. Here is a real world scuttle butt example: I was talking to a girl about here boyfriend and how they met and how she meets guys. She said hinge, instagram tinder. She said hinge for dating, tinder for hook ups. If she mentions Bumble for dating that is a huge endorsement and whoever hears it is virtually certain to try Bumbls. If $BMBL is continuously successful at providing quality matches (Whitney’s goal) it will gain new users->leading to potentially more subscribers->leading to potentially more lost subscribers due to success->who will spread the word and create more inflowing subscribers than out flowing. Word of mouth may be the most powerful advertising force

Investor Letters

All letters

Free Recaps of the best new stock ideas, delivered every morning.

Read past recaps

TSOH Weekly Roundup (10/16/2026)

Bumble agreed to a $1.3 billion take-private deal, while Netflix cut about 1,000 jobs and Meta discussed its Muse superintelligence models.

BMBL $783M
TSOH Investment Research 11 clicks

Is The Market Turning The Page?

CoreWeave’s debt and equity price action is framed as a wake-up call for investors amid a broader market discussion.

CRWV $34B
WHAT ARE WE DOING? “Contrarians At The Gate” 51 clicks
FINV · long

Finvolution Group

FinVolution, a China and ASEAN unsecured consumer lender, trades at 4x earnings and 0.5x book value.

FINV $711M
Value Investors Club

PesoRama: Research Flash

PesoRama will reach 54 JOi Dollar Plus stores by November after raising C$28.4 million, funding more than 50 additional Mexican store…

TBBB $6.8B
Atrium Research - Equity Research 7 clicks

Modine Deep Dive

Modine, soon Modexus Solutions, has a $4 billion hyperscaler cooling contract but must ramp factory output and restore margins as data…

MOD $9.2B
CV's Substack 18 clicks

AppLovin Deep Dive

AppLovin rebuilt its ad model with AXON 2.0, lifting LTM revenue to about $7 billion and margins to 77% as Unity competition threatens…

APP $88B
Speedwell Research 26 clicks

Constellation: Stars Aligning?

Constellation Brands trades near $127 at roughly 11x next-twelve-month EV/EBIT, with recent business results offsetting concerns over…

STZ $22B
TSOH Investment Research 27 clicks

Have a source we’re missing? Send your pick

Recent recaps

Latest recap

Saturday, October 17 31 stock ideas
  • SiriusXM: Dirt Cheap, Looming Catalysts, Short Squeeze Candidate Eagle Point Capital
  • Expert Call | Q3 2026 Optical Components Market Dynamics, Vendor Market Share, & 2027 Growth Outlook P Equity Research
Read the recap

All recaps

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 107

YouTube 4

Blogs 17

Seeking Alpha 52 of 238

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

88 accounts
Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.

Anything we’re missing?

Send us a pick